NanoShunt Product Development Work:
NanoShunt method involves drawing excess CSF from the ventricles of a patient’s brain in a bulk liquid form, converting the CSF from the bulk liquid form into a low-velocity CSF aerosol of ultrafine CSF droplets, and disposing of the CSF aerosol through biological processes. Because of their extremely small droplet size, and the probable reduced pressure in the subcutaneous cavity, the ultrafine CSF droplets evaporate at a body temperature of 37º C. The CSF mist as well as vapors are absorbed into a capillary bed and bloodstream. They also diffuse through the scalp and skin and disposed of as sweat/perspiration..
The NanoShunt device includes a subcutaneous biological atomizer that disposes CSF through fine atomization and vapor transport processes. The atomizer includes an inlet for the introduction of CSF in a bulk liquid form and an outlet for the ejection of CSF in an aerosol form.
When implanted in a patient as an implant, the subcutaneous atomizer will be positioned against the skull and below the scalp of a subject, and joined with a fluid feed transport that is adapted for transporting CSF from the subject and into the atomizer. The CSF feed transport may be provided in the form of a ventricular catheter, with a first end inserted into the ventricles of the patient and a second end joined in fluid communication with the inlet of the atomizer housing.
NanoShunt prototype development involved multiple areas such as electronics control-drivers, physics of excess CSF disposal process, laboratory testing, and cadaver testing. The work is proceeding in parallel.
Small Animal Studies of NanoShunt Implant
The miniaturized implant is now ready and is going for animal study.
A Schematic of implant process and a an example of its placement are shown below